The diagnosis and management of NK/T-cell lymphomas

Table 2 Selected clinical studies on the treatment of stage I/II NK/T-cell lymphoma

Study (reference)	No.	Treatment	ORR	CR	OS	PFS
Retrospective [59]	253	RT (50 Gy)	NR	NR	5-year: 70%	5-year: 65%
Phase II [61, 65]	150	CCRT (50 Gy) + 2/3 DeVIC	89%	82%	5-year: 72%	5-year: 61%
Phase II [63]	30	CCRT (40 Gy) + VIPD	83%	80%	3-year: 86%	3-year: 85%
Phase II [64]	30	CCRT (40 Gy) + VIDL	90%	87%	5-year: 73%	5-year: 60%
Phase II [69, 70]	26	LVP + sandwiched RT (56 Gy)	89%	81%	5-year: 64%	5-year: 64%
Phase II [70, 71]	27	GELOX + sandwiched RT (56 Gy)	96%	74%	5-year: 85%	5-year: 74%
Phase II [73]	33	DICE-L + RT (45 Gy)	91%	100%	5-year: 89%	5-year: 82%
Retrospective [68]	29	SMILE + sandwiched RT (50 Gy)	90%	69%	NR	NR

No. number of patients, ORR overall response rate, CR complete response rate, OS overall survival, PFS progression-free survival, NR not reported, RT radiotherapy, CCRT concurrent chemoradiotherapy, DeVIC dexamethasone, etoposide, ifosfamide, carboplatin, VIDP etoposide, ifosfamide, cisplatin, dexamethasone, VIDL etoposide, ifosfamide, dexamethasone, L-asparaginase, LVP L-asparaginase, vincristine, prednisoloen, GELOX gemcitabine, L-asparaginase, oxaliplatin, DICE-L dexamethasone, ifosfamide, cisplatinum, etoposide, L-asparaginase, SMILE dexamethasone, methotrexate, ifosfamide, L-asparaginase, etoposide

ISSN: 1756-8722